<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03239535</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-CLI/FMBA/001</org_study_id>
    <nct_id>NCT03239535</nct_id>
  </id_info>
  <brief_title>Allogeneic Mesenchymal Stem Cells for the Critical Limb Ischemia Therapy</brief_title>
  <official_title>Allogeneic Mesenchymal Stem Cells for the Critical Limb Ischemia Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Clinical Center of Federal Medical &amp; Biological Agency, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Clinical Center of Federal Medical &amp; Biological Agency, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial aims to study the safety and efficacy of adult allogeneic mesenchymal stem
      cells for the treatment of critical limb ischemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2013</start_date>
  <completion_date type="Anticipated">November 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>Number of adverse events reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amputation-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Number of survived patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Limb salvage from major amputation</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
    <description>Number of patients who avoided amputation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relief of the rest pain</measure>
    <time_frame>Immediate, 3, 6, 12, 24 months</time_frame>
    <description>Rest pain will be measured using the rest pain scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in healing trophic disorders</measure>
    <time_frame>Immediate, 3, 6, 12, 24 months</time_frame>
    <description>Assessment of the severity of trophic ulcers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in perfusion by the ankle-brachial index</measure>
    <time_frame>Immediate, 3, 6, 12, 24 months</time_frame>
    <description>Measurements of the ankle-brachial index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in perfusion by radioisotope scintigraphy</measure>
    <time_frame>Immediate, 3, 6, 12, 24 months</time_frame>
    <description>Radioisotope scintigraphy study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in total walking distance (TWD) using a standard treadmill test</measure>
    <time_frame>Immediate, 3, 6, 12, 24 months</time_frame>
    <description>Standard treadmill test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesenchymal stem cells, Intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline, Intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cells</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females in the age group of 18-80 yrs of Caucasian origin.

          2. Peripheral artery disease (PAD) against the background of atherosclerosis and diabetes
             mellitus (DM)

          3. Critical lower limb ischemia (stages 3-4 by Fontaine-Pokrovsky or stages 4-6 by
             Rutherford)

          4. Patients with remaining symptoms of critical limb ischemia (CLI) in spite of the
             performed surgical (endovascular or open) treatment and continuing conservative
             therapy

          5. Patients with absent emergency indications to major amputation

          6. Patients planned for the reconstructive surgery with a questionable remote outcome due
             to compromised blood outflow

          7. Ankle Brachial Pressure Index (ABPI) ≤ 0.5 or ankle pressure ≤ 70 mm Hg

          8. Patients, if having associated Type II Diabetes, should be on medication and well
             controlled (HbA1c ≤ 8.5 %)

          9. On regular medication for hypertension if needed

         10. Normal liver and renal function (or having clinically insignificant deviations,
             according to the treating physician's opinion)

         11. Patients who are able to understand the requirements of the study, and willing to
             provide voluntary written informed consent, abide by the study requirements, and agree
             to return for required follow-up visits

        Exclusion Criteria:

          1. Humid gangrene or acute/chronic infection of lower limb.

          2. Dry gangrene with extensive foot lesion (&gt; 1\2).

          3. Acute arterial failure.

          4. Life-threatening conditions and predicted life expectancy of &lt; 6 months.

          5. Presence of neoplasm or bone marrow disease

          6. Signs of active or chronic, including latent, haemorrhage

          7. Any acute or chronic infectious disease

          8. Renal failure determined as twofold or higher elevation of serum creatinine as
             compared to the upper normal limit

          9. Hepatic failure determined as the bilirubin, alanine aminotransferase (ALT) or
             aspartate aminotransferase (AST) levels elevated by two and more times over the upper
             normal limits

         10. Thrombocytopenia (platelet counts &lt; 50,000 /µl), leukocytopenia (WBC &lt; 4,000/µl),
             immunosuppressive therapy

         11. Pronounced neurological deficit

         12. Patients with gait disturbance for reasons other than CLI

         13. Patients not suitable for cell therapy, by the treating physician's opinion

         14. CLI patients requiring amputation at the proximal to the trans-metatarsal level

         15. Patients with Type I diabetes

         16. Patients having respiratory complications/left ventricular ejection fraction &lt; 25%

         17. Stroke or myocardial infarction within last 3 months

         18. Patients who are contraindicated for X-ray angiography

         19. History of severe alcohol or drug abuse within 3 months of screening

         20. Pregnant and lactating women.

         21. Patients tested positive for HIV 1, hepatitis C virus (HCV), hepatitis B virus (HBV)

         22. Unsigned informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir P Baklaushev, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Deputy Director</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pavel Yu Orekhov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vascular Surgeon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikhail A Konoplyannikov, PhD</last_name>
    <phone>+79154027268</phone>
    <email>mkonopl@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Federal Research Clinical Center of Federal Medical &amp; Biological Agency</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail A Konoplyannikov, PhD</last_name>
      <phone>+79154027268</phone>
      <email>mkonopl@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2017</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

